Randomized controlled trialHuman
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
The New England journal of medicine, 2016 Nov 10. Marso SP, Bain SC, Consoli A and 13 others.
Study type
Randomized controlled trial
Subjects
Human participants (PubMed MeSH: Humans)
Journal
The New England journal of medicine
Published
2016 Nov 10
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AgedCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic NephropathiesDiabetic RetinopathyFemaleGastrointestinal DiseasesGlucagon-Like Peptide 1Glucagon-Like PeptidesGlycated HemoglobinHumansKaplan-Meier Estimate
Other papers on Semaglutide
Randomized controlled trial · 2025
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
Randomized controlled trial · 2023Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Randomized controlled trial · 2021Once-Weekly Semaglutide in Adults with Overweight or Obesity
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page